Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2019 Apr;17(5):976-987.e4. doi: 10.1016/j.cgh.2018.10.031. Epub 2018 Oct 26.

Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis.

Author information

1
Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Department of Health Policy and Management, School of Public Health, College Station, Texas.
2
Department of Health Policy and Management, School of Public Health, College Station, Texas; Population Informatics Laboratory, Texas A&M University, College Station, Texas; Department of Industrial and Systems Engineering, Texas A&M University, College Station, Texas.
3
Population Informatics Laboratory, Texas A&M University, College Station, Texas; Department of Industrial and Systems Engineering, Texas A&M University, College Station, Texas.
4
Department of Health Policy and Management, School of Public Health, College Station, Texas; Population Informatics Laboratory, Texas A&M University, College Station, Texas.
5
Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
6
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
7
Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas. Electronic address: amit.singal@utsouthwestern.edu.

Abstract

BACKGROUND & AIMS:

Hepatocellular carcinoma (HCC) screening of patients with cirrhosis is recommended by professional societies to increase detection of early stage tumors and survival, but is underused in clinical practice.

METHODS:

We conducted a retrospective cohort study of 13,714 patients diagnosed with HCC from 2003 through 2013 included in the Surveillance, Epidemiology, and End Results Program-Medicare database. We characterized receipt of HCC screening in the 3 years before HCC diagnosis using mutually exclusive categories (consistent vs inconsistent vs no screening) and the proportion of time covered with screening. Correlates for screening receipt were assessed using a multivariable 2-part regression model. We examined the association between screening receipt and early detection of tumors using multivariable logistic regression. We evaluated associations between screening receipt and overall survival using a Cox proportional hazards model, after adjustments for effects of lead-time bias and length-time bias on survival rate estimators.

RESULTS:

Most patients with cirrhosis (51.1%) did not receive any screening in the 3 years before a diagnosis of HCC, and only 6.8% of patients underwent consistent annual screening. The proportion with consistent screening increased from 5.4% in 2003 to 2006 to 8.8% in 2011 to 2013 (P < .001). The mean proportion of time covered was 13.4% overall, which increased from 11.7% in 2003 to 2006 to 15.2% in 2011 to 2013. Receipt of consistent screening was associated with detection of early stage tumors (odds ratio, 1.98; 95% CI, 1.68-2.33) and a reduced risk of death after correction for lead-time bias (hazard ratio, 0.76; 95% CI, 0.70-0.83). Inconsistent screening was associated with a slightly smaller increase in early detection of HCC (odds ratio, 1.31; 95% CI, 1.20-1.43) and a reduced risk of death (hazard ratio, 0.86; 95% CI, 0.83-0.90). After correction for lead- and length-time biases, higher proportions of patients with consistent (23%; 95% CI, 21%-25%) and inconsistent screening (19%; 95% CI, 19%-20%) survived for 3 years compared with patients without screening (13%; 95% CI, 12%-14%).

CONCLUSIONS:

In an analysis of the Surveillance, Epidemiology, and End Results Program-Medicare database, we found HCC screening to be underused for patients with cirrhosis. This contributes to detection of liver tumors at later stages and shorter times of survival. However, the proportion of patients screened for HCC has increased over time.

KEYWORDS:

Liver Cancer; SEER Database Analysis; Screening; Ultrasound

PMID:
30616961
PMCID:
PMC6431264
[Available on 2020-04-01]
DOI:
10.1016/j.cgh.2018.10.031

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center